{"id":3803,"date":"2025-03-31T18:11:50","date_gmt":"2025-03-31T18:11:50","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/candesartan-cilexetil-txt\/"},"modified":"2025-03-31T18:11:50","modified_gmt":"2025-03-31T18:11:50","slug":"candesartan-cilexetil-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/candesartan-cilexetil-txt\/","title":{"rendered":"Candesartan cilexetil.txt"},"content":{"rendered":"

Candesartan cilexetil<\/h1>\n

CLINICAL USE <\/H3>
\nAngiotensin-II antagonist:<\/p>\n
  • Hypertension\n
  • Heart failure

    DOSE IN NORMAL RENAL FUNCTION <\/H3>2\u201332 mg daily

    PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :610.7<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :>99<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 26<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.1<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :9\/18

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Initial dose 2 mg and increase according to response
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Initial dose 2 mg and increase according to response

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as for GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as for GFR <10 mL\/min
  • HDF\/high flux &nbsp :Not dialysed. Dose as for GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as for GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anaesthetics: enhanced hypotensive effect Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs\n
  • Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity\n
  • Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics\n
  • Epoetin: increased risk of hyperkalaemia; antagonism of hypotensive effect\n
  • Lithium: reduced excretion, possibility of enhanced lithium toxicityP\n
  • otassium salts: increased risk of hyperkalaemia.\n
  • Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>\n
  • In patients with mild\u2013moderate renal impairment Cmax and AUC are increased by 50% and 70% respectively. Corresponding changes in patients with severe renal impairment are 50% and 110% respectively\n
  • Adverse reactions, especially hyperkalaemia, are more common in patients with renal impairment\n
  • Renal failure has been reported in association with angiotensin-II antagonists in patients with renal artery stenosis, post renal transplant, and in those with congestive heart failure\n
  • Close monitoring of renal function during therapy is necessary in those with renal insufficiency
    \n","protected":false},"excerpt":{"rendered":"

    Candesartan cilexetil CLINICAL USE Angiotensin-II antagonist: Hypertension Heart failure DOSE<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3803","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3803"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3803\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}